1. Home
  2. BNR vs TSI Comparison

BNR vs TSI Comparison

Compare BNR & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

N/A

Current Price

$22.81

Market Cap

252.7M

Sector

Health Care

ML Signal

N/A

Logo TCW Strategic Income Fund Inc.

TSI

TCW Strategic Income Fund Inc.

N/A

Current Price

$4.62

Market Cap

221.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BNR
TSI
Founded
2014
1987
Country
China
United States
Employees
674
N/A
Industry
Medical Specialities
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
252.7M
221.7M
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
BNR
TSI
Price
$22.81
$4.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.1K
324.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
7.46%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$136.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$4.57
52 Week High
$41.72
$5.06

Technical Indicators

Market Signals
Indicator
BNR
TSI
Relative Strength Index (RSI) 40.95 40.04
Support Level $7.99 $4.58
Resistance Level $24.23 $4.70
Average True Range (ATR) 2.07 0.05
MACD -0.41 0.01
Stochastic Oscillator 29.88 47.36

Price Performance

Historical Comparison
BNR
TSI

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.

Share on Social Networks: